AMGN
HealthcareAMGEN Inc
$331.11+1.52 (+0.46%)LIVE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving AMGN Today?
No stock-specific AI insight has been generated for AMGN yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$178.8B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding540.0M
AMGN News
49 articles- Ethic Inc. Boosts Stock Position in Amgen Inc. $AMGNMarketBeat·May 9, 2026
- Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF CaseSimply Wall Street·May 9, 2026
- Assessing Regeneron (REGN) After Recent Share Price Weakness And Strong Valuation SignalsSimply Wall Street·May 8, 2026
- 2 Dividend Stocks to Double Up On Right NowMotley Fool·May 8, 2026
- FY2026 EPS Estimates for Amgen Boosted by Erste Group BankMarketBeat·May 8, 2026
- GRIMES & Co WEALTH MANAGEMENT LLC Sells 4,111 Shares of Amgen Inc. $AMGNMarketBeat·May 8, 2026
- Generali Asset Management SPA SGR Raises Stake in Amgen Inc. $AMGNMarketBeat·May 8, 2026
- [Form 4] AMGEN INC Insider Trading ActivityStock Titan·May 8, 2026
- Amgen (NASDAQ: AMGN) director receives stock award and updates holdingsStock Titan·May 8, 2026
- [Form 4] AMGEN INC Insider Trading ActivityStock Titan·May 8, 2026
- AMGEN TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH GLOBAL HEALTHCARE CONFERENCEPR Newswire·May 7, 2026
- IgG4-Related Disease Market Analysis and Forecasts, 2025-2026 & 2035 with Amgen, Zenas BioPharma, Bristol Myers Squibb, and Sanofi LeadingYahoo Finance·May 7, 2026
- Zai Lab Announces First Quarter 2026 Financial Results and Recent Corporate UpdatesYahoo Finance·May 7, 2026
- As AI Rewrites Drug Development, the Industry Gathers in Philadelphia to Work Out the RulesYahoo Finance·May 6, 2026
- Amgen’s US$300m Biologics Push And What It Means For AMGN StockYahoo Finance·May 6, 2026
- RPRX vs. AMGN: Which Stock Is the Better Value Option?Yahoo Finance·May 6, 2026
- Timothy P. Walbert Joins Patient Square Capital as a Senior AdvisorYahoo Finance·May 6, 2026
- How This Amgen Rival, Up 33%, Plans To Shake Its Grip In Thyroid Eye DiseaseYahoo Finance·May 5, 2026
- Viridian data lift prospects for thyroid eye disease drugBiopharmadive·May 5, 2026
- 2 Nasdaq 100 Stocks with Competitive Advantages and 1 We QuestionYahoo Finance·May 5, 2026
- What’s at stake in Amgen’s showdown with the FDA?Pharmavoice·May 5, 2026
- Sector Update: Health Care Stocks Softer in Afternoon TradingYahoo Finance·May 4, 2026
- Amgen invests $300M more in Puerto Rico biologics plantQz·May 4, 2026
- Guggenheim Trims Amgen Price Target to $340: Is the Biotech Giant Losing Its Edge?247 Wall St·May 4, 2026
- 3 Top Dividend Stocks to Maximize Your Retirement IncomeYahoo Finance·May 4, 2026
- Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should KnowYahoo Finance·May 4, 2026
- AMGEN ANNOUNCES ADDITIONAL $300 MILLION U.S. MANUFACTURING INVESTMENT, TOTALING NEARLY $2 BILLION OVER THE LAST YEARYahoo Finance·May 4, 2026
- Baron Health Care Fund’s Performance Impacted by Amgen (AMGN) OmissionYahoo Finance·May 4, 2026
- AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in FocusYahoo Finance·May 2, 2026
- FDA Announces Major Steps to Implement Real-Time Clinical TrialsGlobeNewswire Inc.·Apr 28, 2026
- Chronic Obstructive Pulmonary Disease Clinical Trial Landscape Expands: Over 65 Companies Advancing Next-Generation Therapies | DelveInsightGlobeNewswire Inc.·Apr 23, 2026
- Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should KnowThe Motley Fool·Apr 21, 2026
- Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - Clinical Trials, Regulatory Approvals, Development PlatformsGlobeNewswire Inc.·Apr 21, 2026
- Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031 - Insight on More than 550 Clinical Trials - Antibody Dosage, Patent, Price, Sales & OutlookGlobeNewswire Inc.·Apr 21, 2026
- Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical OfficerGlobeNewswire Inc.·Apr 20, 2026
- Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsightGlobeNewswire Inc.·Apr 13, 2026
- Atopic Dermatitis 68-Market Drug Forecast and Market Analysis Report 2023-2025 & 2025-2033GlobeNewswire Inc.·Apr 10, 2026
- Martin Capital Dumps $4.5 Million in Robert Half Shares After a Brutal Year for the Staffing SectorThe Motley Fool·Apr 7, 2026
- Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a DimeInvesting.com·Apr 6, 2026
Price Data
Open$329.13
Previous Close$329.59
Day High$332.98
Day Low$329.05
52 Week High—
52 Week Low—
Fundamentals
Market Cap$178.8B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume2.9M
Avg Volume (10D)—
Shares Outstanding540.0M
About AMGEN Inc
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
HealthcareDrug Manufacturers - General
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICDrug Manufacturers - General
CIK—
Composite FIGI—
Share Class FIGI—